ENZ Stock Overview
A life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Enzo Biochem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.76 |
| 52 Week High | US$1.50 |
| 52 Week Low | US$0.68 |
| Beta | 0.73 |
| 1 Month Change | -21.37% |
| 3 Month Change | -34.25% |
| 1 Year Change | -45.52% |
| 3 Year Change | -76.02% |
| 5 Year Change | -71.22% |
| Change since IPO | -95.88% |
Recent News & Updates
Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some Risk
Dec 18
Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?
Nov 19Recent updates
Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some Risk
Dec 18Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?
Nov 19Enzo Biochem: Is This Time Finally Different?
Jul 17Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
Oct 26Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?
May 18Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Jan 03Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M
Dec 12Enzo Biochem appoints Patricia Eckert as interim CFO
Oct 20Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M
Oct 14Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?
Oct 04Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale
Jun 27Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?
May 03Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
Dec 17Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?
Aug 24Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?
Mar 01Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?
Feb 03If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%
Jan 08
Enzo Biochem nabs expanded EUA nod for testing of COVID samples
Jan 04Enzo Biochem: Betting On The Activists Now
Dec 16Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay
Dec 13Shareholder Returns
| ENZ | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -25.2% | -4.1% | -2.4% |
| 1Y | -45.5% | -10.2% | 23.4% |
Return vs Industry: ENZ underperformed the US Healthcare industry which returned -10.2% over the past year.
Return vs Market: ENZ underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| ENZ volatility | |
|---|---|
| ENZ Average Weekly Movement | 9.9% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENZ has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENZ's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 131 | Kara Cannon | www.enzo.com |
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.
Enzo Biochem, Inc. Fundamentals Summary
| ENZ fundamental statistics | |
|---|---|
| Market cap | US$39.85m |
| Earnings (TTM) | -US$7.21m |
| Revenue (TTM) | US$30.31m |
1.3x
P/S Ratio-5.5x
P/E RatioIs ENZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENZ income statement (TTM) | |
|---|---|
| Revenue | US$30.31m |
| Cost of Revenue | US$16.86m |
| Gross Profit | US$13.46m |
| Other Expenses | US$20.67m |
| Earnings | -US$7.21m |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 44.39% |
| Net Profit Margin | -23.79% |
| Debt/Equity Ratio | 0.5% |
How did ENZ perform over the long term?
See historical performance and comparisonDividends
52.4%
Current Dividend Yield-71%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:04 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Enzo Biochem, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bradley Berning | Craig-Hallum Capital Group LLC |
| Reni Benjamin | Rodman & Renshaw, LLC |
| Jack Wallace | Sidoti & Company, LLC |